Skip to main content
SpringerLink
Log in

Neoadjuvant Chemotherapy: The New Standard

  • Chapter
  • First Online:
Bladder Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1014 Accesses

Abstract

Bladder cancer, most often of the transitional cell type (TCC), is the fourth most commonly diagnosed malignancy in the United States (1). About 75% of patients are diagnosed with localized disease at initial presentation, with about 20% having loco-regionally advanced (stage II/III) disease (2). Following radical cystectomy or definitive radiation therapy, recurrence risk in these patients exceeds 50% (3). Table 22.1 summarizes the data of the recent outcome for patients with locally advanced bladder cancer treated with cystectomy alone.

The high incidence of distant recurrence in patients with presumed early stage disease is principally due to the presence of distant micrometastases at the time of local therapy. Because of this, recent research has revolved around peri-operative systemic therapy, either as neoadjuvant or adjuvant treatment, aimed at eradicating micrometastatic deposits. Alternative (non-cystectomy) approaches for localized disease have also been investigated, particularly radiation therapy with or without chemotherapy. This review summarizes current data on therapeutic strategies for locally advanced bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jamel A, Siegel R, Ward E, Cancer Statistics, 2006. CA Cancer J Clin. 2006, 56(2): 106–130.

    Article  Google Scholar 

  2. SEER Cancer Statistics Review, 1975–2003. National Cancer Institute. www.cancer.gov.

  3. Ghoneim, MA, El-Mekresh MM, Mokhtar AA, A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int. 2000, 85: 811–816.

    Article  CAS  PubMed  Google Scholar 

  4. Stein JP, Cai J, Groshen S, Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001, 19(3): 666–675.

    CAS  PubMed  Google Scholar 

  5. Madersbacher S, Hochreiter W, Burkhard F, Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003, 21(4): 690–696.

    Article  PubMed  Google Scholar 

  6. Scholten AN, Leer JW, Collins CD, et al. Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol. 1997, 43(2): 163–169.

    Article  CAS  PubMed  Google Scholar 

  7. Coppin CM, Gospodarowicz MK, James K, Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996, 14(11): 2901–2907.

    CAS  PubMed  Google Scholar 

  8. Hussain MH, Glass TR, Forman J, Combination cisplatin, 5-fluorouracil and radiation therapy for locally advan-ced unresectable or medically unfit bladder cancer cases: A Southwest Oncology Group Study. J Urol. 2001, 165(1): 56–60.

    Article  CAS  PubMed  Google Scholar 

  9. Wallace DM, Raghavan D, Kelly KA, Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 1991, 67(6): 608–615.

    Article  CAS  PubMed  Google Scholar 

  10. Martinez-Pineiro JA, Gonzalez-Martin M, Arocena F, Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol. 1995, 153(3 Pt 2): 964–973.

    Article  CAS  PubMed  Google Scholar 

  11. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005, 48(2): 202–205.

    Article  Google Scholar 

  12. Brinkley WM, Torti FM. Systemic chemotherapy of transitional cell carcinoma of the urothelium. Semin Surg Oncol. 1997, 13(5): 365–375.

    Article  CAS  PubMed  Google Scholar 

  13. Hall RR. Updated results of a randomized controlled trial of neoadjuvant cisplain (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol. 2002, 21: 178A: abstr 710.

    Google Scholar 

  14. Grossman HB, Natale, RB, Tangen CM, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy along for locally advanced bladder cancer. N Engl J Med. 2003, 349(9): 859–866.

    Article  CAS  PubMed  Google Scholar 

  15. Bassi P, Pappagallo GL, Sperandio P, Neoadjuvant M-VAC chemotherapy for invasive bladder cancer: results of a multicenter phase III trial. J Urol. 1996; 155(suppl): 264: abstr 1021.

    Google Scholar 

  16. Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial (meeting abstract). Proc Am Soc Clin Oncol. 1995, Abstr 623.

    Google Scholar 

  17. Malmstrom PU, Rintala E, Wahlqvist R, Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996, 155: 1903–1906.

    Article  CAS  PubMed  Google Scholar 

  18. Sherif A, Rintala E, Mestad O, Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand J Urol Nephol. 2002, 36: 419–425.

    Article  CAS  Google Scholar 

  19. Sherif A, Holmberg L, Rintala E, Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic Studies. Eur Urol. 2004, 45: 297–303.

    Article  CAS  PubMed  Google Scholar 

  20. Skinner DG, Daniels JR, Russell CA, The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991, 145(3): 459–464.

    CAS  PubMed  Google Scholar 

  21. Stockle M, Meyenburg W, Wellek S, Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol. 1995, 153(1): 47–52.

    Article  CAS  PubMed  Google Scholar 

  22. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblatine, and methotrexate chemotherapy for muscle invasive bladder cancer. U Urol. 1996, 155(2): 495–499.

    Article  CAS  Google Scholar 

  23. Phase III Randomized Study of Immediate versus Deferred Adjuvant chemotherapy after Radical Cystectomy in Patients with Stage III or IV Transitional Cell Carcinoma of the Bladder Urothelium. www.cancer.gov

  24. Millikan R, Dinney C, Swanson D, Integraded therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001, 19(20): 4005–4013.

    CAS  PubMed  Google Scholar 

  25. Von der Maase H, Sengelov L, Roberts JT, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005, 23(21): 4602–4608.

    Article  CAS  PubMed  Google Scholar 

  26. Cohen SM, Goel A, Phillips J, The role of perioperative chmeotherapy in the treatment of urothelial cancer. Oncologist. 2006, 11: 630–640.

    Article  CAS  PubMed  Google Scholar 

  27. Tsavaris N, Kosmas C, Skopelitis H, Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study. J Chemother. 2005, 17(4): 441–448.

    CAS  PubMed  Google Scholar 

  28. Bamias A, Moulopoulos LA, Koutras A, The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer. 2006, 106(2): 297–303.

    Article  CAS  PubMed  Google Scholar 

  29. Smith DC, Mackler NJ, Hussain MH, Neoadjuvant paclitaxel (P), carboplatin (Ca), and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report. Proc Am Soc Oncol. 2006, 24(18s): 226s: Abstr 4541.

    Google Scholar 

  30. Burch PA, Richardson RL, Cha SS, Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol. 2000, 164(5): 1538–1542.

    Article  CAS  PubMed  Google Scholar 

  31. Garcia del Muro X, Marcuello E, Guma J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer. 2002, 86(3): 326–330.

    Article  CAS  PubMed  Google Scholar 

  32. Sousa-Escandon A, Vazquez S, Quintero-Aldana G, Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial. Int J Urol. 2002, 9(3): 162–166.

    Article  CAS  PubMed  Google Scholar 

  33. Barmias A, Delveliotis C, Karayiannis A, Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results. Eur Urol. 2004, 46: 344–350.

    Article  Google Scholar 

  34. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001, 19(1): 89–93.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, University of California, Davis Cancer Center, Sacramento, CA, USA

    Karen Giselle Chee & Primo N. Lara

Authors
  1. Karen Giselle Chee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Primo N. Lara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Primo N. Lara .

Editor information

Editors and Affiliations

  1. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    Cheryl T. Lee

  2. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    David P. Wood

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chee, K.G., Lara, P.N. (2009). Neoadjuvant Chemotherapy: The New Standard. In: Lee, C., Wood, D. (eds) Bladder Cancer. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-417-9_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-417-9_22

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-988-8

  • Online ISBN: 978-1-59745-417-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation